Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
The experiences of patients with musculoskeletal conditions accessing first contact physiotherapy practitioner appointments in general practice in the UK: A qualitative study.
Journal: Musculoskeletal care
Published: May 15, 2024
Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept study.
Journal: Annals of the rheumatic diseases
Published: December 18, 2023
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Journal: Annals of the rheumatic diseases
Published: May 25, 2023
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
Journal: Annals of the rheumatic diseases
Published: May 18, 2023
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).
Journal: The European respiratory journal
Published: July 02, 2021
Targeting GM-CSF in rheumatological conditions: risk of PAP - Authors' reply.
Journal: The Lancet. Rheumatology
Published: March 23, 2021
CCL17 in Inflammation and Pain.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: March 23, 2020
GM-CSF Primes Proinflammatory Monocyte Responses in Ankylosing Spondylitis.
Journal: Frontiers in immunology
Published: March 05, 2020
IL-23 in arthritic and inflammatory pain development in mice.
Journal: Arthritis research & therapy
Published: February 05, 2020
Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial.
Journal: The Lancet. Rheumatology
Published: December 20, 2019
MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study.
Journal: The Lancet. Rheumatology
Published: December 20, 2019
Granulocyte-Macrophage Colony Stimulating Factor As an Indirect Mediator of Nociceptor Activation and Pain.
Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience
Published: September 16, 2019
Last Updated: 09/26/2026